This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
by Zacks Equity Research
Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.
The Zacks Analyst Blog Highlights Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs
by Zacks Equity Research
Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs are part of the Zacks top Analyst Blog.
Top Stock Reports for Alphabet, Roche & Honeywell International
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Roche Holding AG (RHHBY) and Honeywell International Inc. (HON).
Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
by Kinjel Shah
FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
by Zacks Equity Research
Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
by Zacks Equity Research
Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth
by Zacks Equity Research
Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.
Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H
by Zacks Equity Research
Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
by Zacks Equity Research
Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.
Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.
Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.
Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
by Zacks Equity Research
In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.
Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche
by Zacks Equity Research
Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.
Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use
by Zacks Equity Research
Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.